Actively Recruiting
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Led by Metsera, a wholly owned subsidiary of Pfizer · Updated on 2026-02-03
132
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
CONDITIONS
Official Title
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI 47 27 kg/m2 and 47 38.0 kg/m2 (inclusive) at screening
- For Parts A and B, no history of clinically significant diseases or findings from physical exam
- For Part C, no clinically significant diseases except well controlled type 2 diabetes, hypertension, or dyslipidemia
- For Part C, diagnosed with type 2 diabetes for at least 3 months before screening
- For Part C, glycated hemoglobin (HbA1c) value 47 10.5% at screening and stable diabetes therapy for at least 30 days prior to screening/Visit 1
You will not qualify if you...
- Female who is pregnant or lactating at screening or Day 1
- Seated blood pressure higher than 160/100 mmHg at screening or before first drug dose
- Resting pulse greater than 100 beats per minute at screening or before first drug dose
- Estimated glomerular filtration rate (eGFR) less than 80 mL/min at screening
- Diagnosis of type 1 diabetes
- For Parts A and B: diagnosis of type 2 diabetes or HbA1c 47 6.4% or fasting plasma glucose 47 126 mg/dL or history of glucose-lowering medications
- For Parts A and B: weight-related comorbidities including sleep apnea and cardiovascular disease
- History of bariatric or weight loss surgeries
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome
- Lifetime history of acute or chronic pancreatitis or pancreatic cancer
- Participation in weight loss program with or without medication during 3 months prior to study or plans to do so
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site MET233/097 24-101-001
Cypress, California, United States, 90630
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here